CVS refused to cover Yeztugo, Gilead’s $28,000-a-year injectable PrEP, preventing patients from accessing the HIV prevention ...

Advocates have claimed that CVS’s refusal to cover Yeztugo violates the Affordable Care Act (ACA), which requires insurers to ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

CVS Health, one of the nation’s largest pharmacy benefit manager companies that play a lead role in deciding which drugs are ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in ...

On Friday, the U.S. District Court for the District of Maryland paused several parts of a health insurance exchange enrollment and eligibility rule that was set to take effect today. The court agreed ...

The EC approved lenacapavir, GILD’s twice-yearly injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrEP ...